New York Attorney General Letitia James has secured more than $2.7 billion in total for New York from opioid manufacturers, distributors and marketers.
The high-concentration interchangeable biosimilar to AbbVie Biotechnology's Humira manufactured by Alvotech will be distributed under Quallent’s private-label.